BioTerp Partners Final Performance
S&P 500 TR: +18.4%
12/17/14 close to 1/31/17
Net of Fees
Zack Fink, 24, is Co-Founder and Portfolio Manager of BioTerp Partners (BTP) with an investment focus on gene therapy, immunotherapy, and other areas with unmet needs.
BioTerp Partners is a closed non-leveraged biotechnology portfolio, managed by Zack Fink.
BioTerp Partners is not registered with any regulatory body and wasn't available for public participation.
"We have discovered the secret of life."
- Francis Crick February 1953
Zack has always had a broad interest in the medical field, stemming from his chronic back problems and
numerous back surgeries. His keen interest and passion specifically for biotechnology was spurred by the sudden passing of his father, Mitchell Fink, 18 years after being diagnosed with Multiple Myeloma and Acute Myeloid Leukemia.
He also contributes to PropThink.com where he works collaboratively with PropThink's team to publish actionable investment ideas. Zack graduated from The University of Maryland in the spring of 2015 with a bachelor's degree in Bioengineering.
Zack can be contacted by email at: firstname.lastname@example.org.